Alvita Pharma Private Limited (APPL) is a pharmaceutical company headquartered in Mumbai, India. It has a strong presence in Branded Generic business in more than 25 countries across 3 continents of Africa, South East Asia and Eastern Europe. Alvita is marketing more than 600 products in most therapeutic segments such as anti-malarial, gastrointestinal, antibiotics, cardiology, dermatology, pain management, etc. Alvita has advanced research facilities for formulation and product development located in Mumbai and Vadodara. It also has many firsts to market products launched in different countries that provide access to patients to high quality and affordable medicines. Its new manufacturing unit in Vadodara is fully operational and expected to obtain European Union approval by March, 2023. Alvita’s joint venture has provided fully backward integrated API (Active pharmaceutical ingredient) unit capability to further improve cost efficiency. Alvita is focusing to build its India business through launching innovative molecules and formulations for which active work in business development and licensing is in process. The company prides itself on its core values of Reliability, Trustworthiness, Adaptability, Accountability and Quality Consciousness. It’s customer base is built on loyalty and the driving principle is “Once a customer, Always our customer”. To further enhance value to our customers, Alvita is constantly expanding its product registration database to address unmet needs of patients in the countries that it operates in.